Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 18/20 | 0.43 |
| ▸ | CA2 | P00918 | 18/20 | 0.43 |
| ▸ | CA4 | P22748 | 8/20 | 0.43 |
| ▸ | CA12 | O43570 | 4/20 | 0.43 |
| ▸ | CA9 | Q16790 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15499792 | 0.70 | CA1 (0.75) | CA1CA2CA4CA12CA9 | |
| SCHEMBL12153724 | 0.67 | TDP1 (0.65) | CA1CA2CA4CA12CA9 | |
| Caldiamide SCHEMBL1114868 | 0.67 | TDP1 (0.65) | CA1CA2CA4CA12CA9 | |
| SCHEMBL18811949 | 0.67 | TDP1 (0.65) | CA1CA2CA4CA12CA9 | |
| SCHEMBL13523700 | 0.67 | CA1 (0.66) | CA1CA2CA4CA12CA9 | |
| SCHEMBL15335281 | 0.66 | CA1 (0.88) | CA1CA2CA4CA12CA9 | |
| Caldiamide SCHEMBL27165225 | 0.66 | TDP1 (0.62) | CA1CA2CA4CA12CA9 | |
| Water SCHEMBL8533754 | 0.66 | TDP1 (0.62) | CA1CA2CA4CA12CA9 | |
| SCHEMBL9159118 | 0.66 | TDP1 (0.64) | CA1CA2CA4CA12CA9 | |
| SCHEMBL791382 | 0.66 | TDP1 (0.64) | CA1CA2CA4CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110250138-A1 | SINGLE-STRANDED AND DOUBLE-STRANDED OLIGONUCLEOTIDES COMPRISING A METAL-CHELATING LIGAND | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110250138-A1 | SINGLE-STRANDED AND DOUBLE-STRANDED OLIGONUCLEOTIDES COMPRISING A METAL-CHELATING LIGAND | SLC40A1, SLCO1B1, SLCO2A1 | CA1 1579/4885CA2 1123/4885CA4 1672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.